NASDAQ:ECYT - Endocyte Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Endocyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/ABeta-0.01 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ECYT Previous Symbol CUSIP29269A10 CIK1235007 Webhttp://www.endocyte.com/ Phone765-463-7175Debt Debt-to-Equity RatioN/A Current Ratio45.80 Quick Ratio45.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$70,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Net Income$-55,060,000.00 Net Margins-32,296.09% Return on Equity-21.19% Return on Assets-20.55%Miscellaneous EmployeesN/A Outstanding Shares82,090,000Market Cap$1.97 billion Next Earnings DateN/A OptionableOptionable Receive ECYT News and Ratings via Email Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter. Endocyte (NASDAQ:ECYT) Frequently Asked Questions What is Endocyte's stock symbol? Endocyte trades on the NASDAQ under the ticker symbol "ECYT." How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) issued its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative return on equity of 21.19%. View Endocyte's Earnings History. Has Endocyte been receiving favorable news coverage? Headlines about ECYT stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Endocyte earned a media sentiment score of -4.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next several days. View News Stories for Endocyte. Who are some of Endocyte's key competitors? Some companies that are related to Endocyte include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX). What other stocks do shareholders of Endocyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Rigel Pharmaceuticals (RIGL), Achaogen (AKAO), Celldex Therapeutics (CLDX), Netflix (NFLX) and Inovio Pharmaceuticals (INO). Who are Endocyte's key executives? Endocyte's management team includes the folowing people: Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)Mr. Michael T. Andriole, Chief Financial Officer (Age 45)Dr. Alison A. Armour, Chief Medical Officer (Age 54)Dr. Christopher P. Leamon, VP of R&D (Age 52)Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70) How big of a company is Endocyte? Endocyte has a market capitalization of $0.00 and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. View Additional Information About Endocyte. What is Endocyte's official website? The official website for Endocyte is http://www.endocyte.com/. How can I contact Endocyte? Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175. MarketBeat Community Rating for Endocyte (NASDAQ ECYT)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 342 (Vote Outperform)Underperform Votes: 274 (Vote Underperform)Total Votes: 616MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: How can investors benefit from after-hours trading?